(Q43796406)

26 November 2017

Phase IB study of 25-hydroxyvitamin D(3) treatment to diminish suppressor cells in head and neck cancer patients (English)

1 reference

26 November 2017

1 reference

1 reference

head and neck carcinoma

1 reference

Lathers DM

1

1 reference

26 November 2017

Clark JI

series ordinal

2

1 reference

26 November 2017

Achille NJ

series ordinal

3

1 reference

26 November 2017

Young MR

series ordinal

4

1 reference

26 November 2017

1 November 2001

1 reference

26 November 2017

1 reference

26 November 2017

62

1 reference

26 November 2017

11

1 reference

26 November 2017

1282-1293

1 reference

Serum and acute phase protein modulation of the effector phase of lymphokine-activated killer cells

26 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0198-8859%2801%2900317-2

7 January 2021

Interleukins and contrasuppression induce immune regression of head and neck cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0198-8859%2801%2900317-2

7 January 2021

Tumour growth causes suppression of autoreactive T-cell proliferation by disrupting macrophage responsiveness to interferon-gamma

1 reference

https://api.crossref.org/works/10.1016%2FS0198-8859%2801%2900317-2

7 January 2021

Phenotypic analysis of nylon-wool-adherent suppressor cells that inhibit the effector process of tumour cell lysis by lymphokine-activated killer cells in patients with advanced gastric carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0198-8859%2801%2900317-2

7 January 2021

Analysis of immunosuppressive mechanism to cytotoxic T lymphocyte generation in patients with advanced cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0198-8859%2801%2900317-2

7 January 2021

Increased presence of CD34+ cells in the peripheral blood of head and neck cancer patients and their differentiation into dendritic cells

1 reference

https://api.crossref.org/works/10.1016%2FS0198-8859%2801%2900317-2

7 January 2021

Differential induction of prostaglandin E2-dependent and -independent immune suppressor cells by tumor-derived GM-CSF and M-CSF

1 reference

https://api.crossref.org/works/10.1016%2FS0198-8859%2801%2900317-2

7 January 2021

Tumor-derived cytokines induce bone marrow suppressor cells that mediate immunosuppression through transforming growth factor beta

1 reference

https://api.crossref.org/works/10.1016%2FS0198-8859%2801%2900317-2

7 January 2021

Mechanisms of immune suppression in patients with head and neck cancer: influence on the immune infiltrate of the cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0198-8859%2801%2900317-2

7 January 2021

Dendritic cell differentiation pathways of CD34+ cells from the peripheral blood of head and neck cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0198-8859%2801%2900317-2

7 January 2021

Cultures derived from peripheral blood CD34+ progenitor cells of head and neck cancer patients and from cord blood are functionally different

1 reference

https://api.crossref.org/works/10.1016%2FS0198-8859%2801%2900317-2

7 January 2021

Myeloid progenitor cells mediate immune suppression in patients with head and neck cancers

1 reference

https://api.crossref.org/works/10.1016%2FS0198-8859%2801%2900317-2

7 January 2021

Synergism of interleukin 6 and 1 alpha,25-dihydroxyvitamin D3 in induction of myeloid differentiation of human leukemic cell lines

1 reference

https://api.crossref.org/works/10.1016%2FS0198-8859%2801%2900317-2

7 January 2021

1alpha,25-dihydroxyvitamin D3 activates T cells of tumor bearers through protein phosphatase 2A

1 reference

https://api.crossref.org/works/10.1016%2FS0198-8859%2801%2900317-2

7 January 2021

Failure of tumor-reactive lymph node cells to kill tumor in the presence of immune-suppressive CD34+ cells can be overcome with vitamin D3 treatment to diminish CD34+ cell levels

1 reference

https://api.crossref.org/works/10.1016%2FS0198-8859%2801%2900317-2

7 January 2021

Vitamin D3 treatment of tumor bearers can stimulate immune competence and reduce tumor growth when treatment coincides with a heightened presence of natural suppressor cells

1 reference

https://api.crossref.org/works/10.1016%2FS0198-8859%2801%2900317-2

7 January 2021

EB1089: a new vitamin D analogue that inhibits the growth of breast cancer cells in vivo and in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0198-8859%2801%2900317-2

7 January 2021

Inhibition of IL-12 production by 1,25-dihydroxyvitamin D3. Involvement of NF-kappaB downregulation in transcriptional repression of the p40 gene.

1 reference

https://api.crossref.org/works/10.1016%2FS0198-8859%2801%2900317-2

7 January 2021

Potent inhibition of dendritic cell differentiation and maturation by vitamin D analogs

1 reference

https://api.crossref.org/works/10.1016%2FS0198-8859%2801%2900317-2

7 January 2021

Vitamin D3 affects differentiation, maturation, and function of human monocyte-derived dendritic cells

1 reference

https://api.crossref.org/works/10.1016%2FS0198-8859%2801%2900317-2

7 January 2021

Inhibition of human T lymphocyte proliferation and cytokine production by 1,25-dihydroxyvitamin D3. Differential effects on CD45RA+ and CD45R0+ cells

1 reference

https://api.crossref.org/works/10.1016%2FS0198-8859%2801%2900317-2

7 January 2021

Vitamin D3 treatment to diminish the levels of immune suppressive CD34+ cells increases the effectiveness of adoptive immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0198-8859%2801%2900317-2

7 January 2021

Skewed differentiation of bone marrow CD34+ cells of tumor bearers from dendritic toward monocytic cells, and the redirection of differentiation toward dendritic cells by 1alpha,25-dihydroxyvitamin D3

1 reference

https://api.crossref.org/works/10.1016%2FS0198-8859%2801%2900317-2

7 January 2021

IL-12: initiation cytokine for cell-mediated immunity

1 reference

https://api.crossref.org/works/10.1016%2FS0198-8859%2801%2900317-2

7 January 2021

Development of TH1 CD4+ T cells through IL-12 produced by Listeria-induced macrophages

1 reference

https://api.crossref.org/works/10.1016%2FS0198-8859%2801%2900317-2

7 January 2021

CD34+ immune suppressive cells in the peripheral blood of patients with head and neck cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0198-8859%2801%2900317-2

7 January 2021

Expression of cytokine mRNA in murine splenic dendritic cells and better induction of T cell-derived cytokines by dendritic cells than by macrophages during in vitro costimulation assay using specific antigens

1 reference

https://api.crossref.org/works/10.1016%2FS0198-8859%2801%2900317-2

7 January 2021

Dendritic cells as initiators of tumor immune responses: a possible strategy for tumor immunotherapy?

1 reference

https://api.crossref.org/works/10.1016%2FS0198-8859%2801%2900317-2

7 January 2021

In vitro propagated dendritic cells from prostate cancer patients as a component of prostate cancer immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0198-8859%2801%2900317-2

7 January 2021

CD83+ blood dendritic cells as a vaccine for immunotherapy of metastatic renal-cell cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0198-8859%2801%2900317-2

7 January 2021

Cellular and humoral immune responses in patients with metastatic renal cell carcinoma after vaccination with antigen pulsed dendritic cells

1 reference

https://api.crossref.org/works/10.1016%2FS0198-8859%2801%2900317-2

7 January 2021

Phase II prostate cancer vaccine trial: report of a study involving 37 patients with disease recurrence following primary treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0198-8859%2801%2900317-2

7 January 2021

Infusion of dendritic cells pulsed with HLA-A2-specific prostate-specific membrane antigen peptides: a phase II prostate cancer vaccine trial involving patients with hormone-refractory metastatic disease

1 reference

https://api.crossref.org/works/10.1016%2FS0198-8859%2801%2900317-2

7 January 2021

Dendritic cell-based immunotherapy of prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0198-8859%2801%2900317-2

7 January 2021

Ineffective immune enhancement by IL-12 in tumor-bearing mice whose immune depression is mediated by suppressive granulocyte-macrophage progenitor cells

1 reference

https://api.crossref.org/works/10.1016%2FS0198-8859%2801%2900317-2

7 January 2021

Vitamin D3 analogue (EB 1089) inhibits in vitro cellular proliferation of human colon cancer cells

1 reference

https://api.crossref.org/works/10.1016%2FS0198-8859%2801%2900317-2

7 January 2021

Vitamin D receptor expression is required for growth modulation by 1 alpha,25-dihydroxyvitamin D3 in the human prostatic carcinoma cell line ALVA-31.

1 reference

https://api.crossref.org/works/10.1016%2FS0198-8859%2801%2900317-2

7 January 2021

Inhibitory effect of 220-oxa-1,25-dihydroxyvitamin D3 on the proliferation of pancreatic cancer cell lines

1 reference

https://api.crossref.org/works/10.1016%2FS0198-8859%2801%2900317-2

7 January 2021

Differential and antagonistic effects of 9-cis-retinoic acid and vitamin D analogues on pancreatic cancer cells in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0198-8859%2801%2900317-2

7 January 2021

The in vitro effect of vitamin D3 analogue EB-1089 on a human prostate cancer cell line (PC-3).

1 reference

https://api.crossref.org/works/10.1016%2FS0198-8859%2801%2900317-2

7 January 2021

Hepatocyte growth factor and vitamin D cooperatively inhibit androgen-unresponsive prostate cancer cell lines

1 reference

https://api.crossref.org/works/10.1016%2FS0198-8859%2801%2900317-2

7 January 2021

A phase I study of the vitamin D analogue EB 1089 in patients with advanced breast and colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0198-8859%2801%2900317-2

7 January 2021

10.1016/S0198-8859(01)00317-2

Identifiers

DOI

1 reference

26 November 2017

1 reference